Search Results - "Lock, V."

A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors by Mahadevan, D., Plummer, R., Squires, M.S., Rensvold, D., Kurtin, S., Pretzinger, C., Dragovich, T., Adams, J., Lock, V., Smith, D.M., Von Hoff, D., Calvert, H.

“…AT7519 is an inhibitor of multiple cyclin-dependent kinases (CDKs). Based on potent antitumor activity in preclinical models, a first-in-human clinical trial…”
Get full text

A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies by Arkenau, H.-T., Plummer, R., Molife, L.R., Olmos, D., Yap, T.A., Squires, M., Lewis, S., Lock, V., Yule, M., Lyons, J., Calvert, H., Judson, I.

“…AT9283 is an inhibitor of aurora kinases A and B with antitumor activity in preclinical models. This a First in Human phase I study assessed the safety,…”
Get full text

293 Activity of the HSP90 Inhibitor, AT13387, in ALK-driven Tumor Models by Wallis, N, Smyth, T, Munck, J, Rodriguez-Lopez, A, Lock, V, McMenamin, R, Thompson, N, Lyons, J

Get full text

Developing a cyberbullying conceptual framework for educators by Redmond, Petrea, Lock, Jennifer V., Smart, Victoria

“…In today's technologically enhanced and changing world, incidents of cyberbullying are increasing and it is a reality that impacts children and adults…”
Get full text

Designing learning to engage students in the global classroom by Lock, Jennifer V.

“…The purpose of the article is to examine how the paradigm shift in education and the availability of digital technologies have created new opportunities to…”
Get full text

596 Design and validation of pharmacodynamic assays to measure the activity of the HSP90 inhibitor, AT13387 in surrogate tissue and tumor in a phase I study by Lyons, J, Squires, M, Lock, V, Graham, B, Smyth, T, Ong, E, Mahadevan, D, Kwak, E, Shapiro, G

Get full text

A flexible framework for online collaborative learning by Redmond, Petrea, Lock, Jennifer V.

“…This paper presents a framework for online collaborative learning, also known as telecollaboration. At the centre of this flexible framework are online…”
Get full text

Pre-service teachers' perspectives of cyberbullying by Redmond, Petrea, Lock, Jennifer V., Smart, Victoria

“…For over a decade practitioners and researchers have been concerned about cyberbullying within educational contexts. Few tools exist to explore this complex…”
Get full text

Assessing Research Readiness of Graduate Students in Distance Programs by Pival, Paul R., Lock, Jennifer V., Hunter, Maureen

“…The aim of this descriptive research study was to assess the skill level, confidence, and overall research readiness of selected groups of graduate students…”
Get full text

Phase I pharmacokinetic and pharmacodynamic study of the heat shock protein 90 inhibitor AT13387 in patients with refractory solid tumors by Shapiro, G., Kwak, E. L., Dezube, B. J., Lawrence, D. P., Cleary, J. M., Lewis, S., Squires, M., Lock, V., Lyons, J. F., Yule, M.

“…Abstract only…”
Get full text

A phase I study of AT9283, an aurora kinase inhibitor, in patients with refractory solid tumors by Kristeleit, R., Calvert, H., Arkenau, H., Olmos, D., Adam, J., Plummer, E. R., Lock, V., Squires, M., Fazal, L., Judson, I.

“…Abstract only 2566 Background: AT9283, a multitargeted kinase inhibitor, inhibits several closely related tyrosine and serine/threonine kinases with an IC50 of…”
Get full text

A dose escalation, pharmacokinetic, and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors by Mahadevan, D., Plummer, R., Squires, M. S., Rensvold, D., Dragovich, T., Adams, J., Lock, V., Smith, D., Von Hoff, D. D., Calvert, H.

“…Abstract only…”
Get full text

Hospital readmissions. We'll meet again by Levy, A, Alsop, K, Hehir, M, Lock, V, Greenwood, R, Tobin, G

“…A 12-month study of emergency medical admissions at one trust suggests most readmissions could not be avoided. The re-admission rate within 28 days was 10 per…”
Get more information

A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies by Arkenau, H-T, Plummer, R, Molife, L R, Olmos, D, Yap, T A, Squires, M, Lewis, S, Lock, V, Yule, M, Lyons, J, Calvert, H, Judson, I

“…AT9283 is an inhibitor of aurora kinases A and B with antitumor activity in preclinical models. This a First in Human phase I study assessed the safety,…”
Get full text

Improved localisation for radical treatment of breast carcinoma using CT and ultrasound by Lock, V, Coules, D

Get more information

285 POSTER AT7519, a selective small molecule inhibitor of cyclin dependent kinases: pharmacodynamic biomarker activity in a Phase I study by Lyons, J., Sweeney, P., Lock, V., Squires, M., Thompson, N., Gallagher, N.

Get full text

Structure of Ribose Anhydride by JEANLOZ, R. W, BARKER, G. R, LOCK, M. V

Get full text

A New Image: Online Communities to Facilitate Teacher Professional Development by Lock, Jennifer V

“…Realizing the potential of online or virtual communities to facilitate teacher professional development requires educators to change their current perceptions…”
Get more information

Winifred Mary McKenzie 1906-1986. A tribute by Lock, G V

Get more information

Nursing research by Lock, M V

Get more information